ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
Status:
Recruiting
Trial end date:
2024-10-31
Target enrollment:
Participant gender:
Summary
First-in Human study evaluating the safety, tolerability and efficacy of ENB003 in
combination with Pembrolizumab in solid tumors. The study is separated into two parts. Part A
is a 3+3 dose escalation to define the recommended RP2D; this part will include metastatic
melanoma, platinum resistant ovarian cancer, and pancreatic cancer patients subjects, but
other solid tumors will be allowed. Once the RP2D is selected, the study will be expanded
into metastatic melanoma, platinum resistant ovarian cancer, and pancreatic cancer subjects.
A small number of sarcoma subjects will be included, as exploratory.